These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38965463)

  • 21. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
    Pensato U; Baraldi C; Favoni V; Mascarella D; Matteo E; Andrini G; Cainazzo MM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
    Cephalalgia; 2022 Jun; 42(7):645-653. PubMed ID: 35135357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
    Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
    J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
    Pensato U; Baraldi C; Favoni V; Cainazzo MM; Torelli P; Querzani P; Pascazio A; Mascarella D; Matteo E; Quintana S; Asioli GM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
    Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
    J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
    Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
    Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
    Ashina M; Cohen JM; Gandhi SK; Du E
    Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study.
    Krymchantowski A; Jevoux C; Krymchantowski AG; Silva-Néto RP
    Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):181-185. PubMed ID: 37748000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
    J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
    Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
    Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
    Kaltseis K; Hamann T; Gaul C; Broessner G
    Headache; 2022 Nov; 62(10):1264-1271. PubMed ID: 36437611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.
    Cainazzo MM; Baraldi C; Ferrari A; Lo Castro F; Pani L; Guerzoni S
    Neurol Sci; 2021 Oct; 42(10):4193-4202. PubMed ID: 33547541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective real-world analysis of erenumab in refractory chronic migraine.
    Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
    J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S;
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.